Young cancer survivor touches senator

from NEWS & RECORD
news-record.com

Greensboro, North Carolina
By: Doug Clark, Staff Writer

Lung Cancer Alliance Calls American Cancer Society's Claim of Progress Selective

Lung Cancer Alliance (LCA) said that the American Cancer Society's claim of "progress in cancer fight" earlier this week was based on "selective culling of statistics and ignores the dismal truth that we have made very little progress on the most lethal cancers, including lung cancer, which causes one in every two cancer deaths, or in metastatic cancer of any kind."

LCA President & CEO Laurie Fenton Ambrose agreed that progress has been made with certain cancers such as breast, prostate and colon which have widely accepted screening tests for early detection and ACS deserves credit for promulgating information to the public on the importance of these tests.

"But this is not time to be celebrating when half of all cancers still have survival rates of less than 50% and when we are facing a 45% increase in the overall number of new cancer cases by the year 2030," she said, citing a recent report on the upcoming tidal wave in the Journal of Clinical Oncology.

"There could be no stronger wake-up call," she said. "We can't continue to tout selected changes in incidence and mortality rates over a limited number of cancers over a limited period of time. We have to step back and look at the big picture and try to figure out why we have not done better and where we have to go from here."

Read more.

Spring issue of CR magazine reports: The High Costs of Cancer Mortality

A new analysis helps put research funding into perspective
By Hannah Hoag

...new studies found that at least 25 percent of cancer’s costs could be attributed to lung cancer. In 2008, an estimated 161,840 people died of the disease in the U.S., far more than died of any other cancer. The researchers further calculated that if lung cancer mortality rates declined by 1 percent annually, the value of life lost in 2020 due to lung cancer would drop from a projected $433 billion to $355 billion. A 4 percent annual decline in these mortality rates would put the estimated value of life lost to lung cancer in 2020 at $192 billion.

“The issue with lung cancer is that we are so naive about what we really know,” says Regina Vidaver, the executive director of the National Lung Cancer Partnership. “We need more knowledge in every single aspect, certainly in understanding [cell] signaling pathways and where they go wrong in cancer initiation and drug-resistance development.”

Even so, Laurie Fenton Ambrose, the president and chief executive officer of the Lung Cancer Alliance, is optimistic that a 1 percent annual decline in mortality is possible with additional funding for lung cancer research, including efforts aimed at finding cancers earlier. “Most cancers that have seen improvements are due to a more robust mechanism to detect their cancers early,” she says.

Read more.

Lung Cancer Alliance to Canadian Medical Association Journal Editorial on Lung Cancer Screening

Monday, April 20, 2009: Last week, the Canadian Medical Association Journal published an editorial discussing lung cancer screening. In the piece, they misrepresented LCA's position on lung cancer screening. In addition, they came to the conclusion that the best use of funding for lung cancer would be in tobacco control and cessation programs. LCA President & CEO, Laurie Fenton Ambrose, sent in a Letter to the Editor of the Canadian Medical Association Journal clarifying LCA's position on lung cancer screening and urging those within the community to address the disease in a comprehensive manner with tobacco cessation programs, early detection and treatment research.

View the Canadian Medical Association Journal Editorial

LCA's response: (Text Below)

Dear Editor,

The editorial in the April 14, 2009 Canadian Medical Association Journal entitled "A Pause for Thought on Lung Cancer Screening", by M.B. Stanbrook and K. Flegel accuses the Lung Cancer Alliance of having "promoted" CT screening for lung cancer. For the record, our position is that those at high risk for lung cancer (those with greater than 20 pack year smoking history, those with a family history of lung cancer, those with exgtensive exposure to asbestos, radon, Agent Orange and other carcinogens) should speak with their doctors about the risks and benefits of a CT scan.

Please note that we emphasize those at high risk, not population based screening. Even before mammograms and psa testing became widely accepted population based screening tests in the US. (The 5-year survival rates for those cancers are now 88% and 99% respectively and whether or not screening played a role in this increase in survival rates you can debate). The 5-year survival rate for lung cancer is still only 15%.

Lung cancer is far more lethal for the individual patient and in its overall public health impact. Nearly one in every three cancer deaths in the United States is due to lung cancer and only 16% of patients are being diagnosed at an early, most curable stage. Advances in CT scanning now present an alternative to late stage diagnosis for those at hight risk and recent papers coming out of ongoing European trials are further refining the process of CT screening.

Certainly we can look forward to a simple biomarker to further refine the optimal population subset for a CT scan, and we have adocated strongly for reseach funding in these areas. But in the meantime are you suggesting that those at high risk should do nothing? Your conclusion is: "In the meantime, given how much we know about the prevention of lung cancer, targeting smoking avoidance and cessation, rather than detection and management of lung cancer, would seem a better investment."

Sadly this statement ignores the fact that over 50% of lung cancer is being diagnosed in people who have already quit, many of them decades ago. Another 15 to 20% have never smoked. Without considering these individuals,any investment analysis in lung cancer in 2009 and the future is incomplete and suspect.

Sincerely,
Laurie Fenton Ambrose
President & CEO
Lung Cancer Alliance

Read more about the Lung Cancer Alliance's effort to fight back against lung cancer.

Breath of Hope: Lung Cancer The Invisible Disease

A new lung cancer documentary has been released and has started airing on Public Broadcasting Service (PBS) Stations across the country.

“Breath of Hope: Lung Cancer The Invisible Disease” is an hour long documentary that profiles lung cancer survivors from across the country, including LCA-MA advocate Kevin Brumett.

Hosted by Emmy and Golden Globe Award-winning actress S. Epatha Merkerson of Law and Order fame, “Breath of Hope” attempts to eradicate the stigma of lung cancer by sharing the perspectives of survivors and their families as well as information from leading experts in the field.

The documentary, produced by CRW Productions in partnership with CancerCare and with input from LCA, has aired in more than 15 major markets, showing the true face of the disease in San Francisco, Philadelphia, Denver, Orlando, Indianapolis and Knoxville, TN.

For more information about “Breath of Hope”, or to see where and when it will air, please visit the documentary website, http://breathofhope.net/.